Glyceryl - trinitrate
ApprovedSmall molecule
Glyceryl - trinitrate is one of 173 small molecule programs targeting Erectile Dysfunction. It is currently in Approved.
6
Indications
10
Total Trials
0
Active Trials
172
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Glyceryl - trinitrate
PProcris Pharmaceuticals
Approved
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Zocor
OOrganon and Co
Preclinical
Depakote
AbbViePreclinical
Lunesta
Akero TherapeuticsPreclinical
Comtan
Orion Corporation, Orion PharmaPreclinical
Inversine
TTargacept Inc.
Preclinical
Permax
VValeant Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Anal fissure2 trials
Pancreatitis1 trial
Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)
Terminated·—·Phase 2/3·NCT00419549·371 enrolled
Tendinopathy1 trial
Angina Pectoris1 trial
Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris
Unknown status·GGuang'anmen Hospital of China Academy of Chinese Medical Sciences·Phase 4·NCT04661709·502 enrolled
4 more indications
Erectile Dysfunction1 trial
Blood Pressure1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Glyceryl - trinitrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- PProcris Pharmaceuticals